IMCD stock: IMCD schedules November 5 results for IMCD stock

Published on 10/23/2026 at 01:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IMCD will publish first nine-month results on November 5, 2026 at 7:00 a.m. CET. IMCD stock's 2025 revenue was EUR 4.78 billion, up 5 percent.

Reporting and valuation

IMCD announced its nine-month reporting date on October 15, 2026.
First-half 2026 revenue reached EUR 2.65 billion, up 6.60 percent year over year.
IMCD stock closed at EUR 100.60 on October 22, 2026, on Xetra.
Goldman Sachs assigned a EUR 133.00 target on October 4, 2026.

Isometrische 3D-Illustration einer Lieferkette mit Lagerhallen, Schiffen, Lastwagen und Chemieanlagen — Isometrische 3D-Grafik der Wertschöpfungskette illustriert Logistikprozess von IMCD N.V., ISIN NL0010801007, schematisch dargestellt, Illustration mit AI erstellt.

IMCD (ISIN NL0010801007) will publish its first nine-month 2026 results on November 5, 2026, giving the specialty chemicals distributor its next major test after first-half revenue reached EUR 2.65 billion. The date was announced in a company release distributed by Globenewswire on October 15, 2026. For investors, the figures will show whether the recovery in operating performance continued into the third quarter.

November 5 sets the next test

IMCD's release schedules publication for 7:00 a.m. CET on November 5, 2026, followed by an analyst conference call and webcast at 9:00 a.m. CET. The presentation will also be posted at 7:00 a.m. CET, according to Globenewswire.

The timing matters because IMCD entered the second half with mixed but improving operating signals. Its first-half 2026 revenue was EUR 2.65 billion, 6.60 percent above the comparable period, while net income reached EUR 142.30 million, up 9.70 percent, according to Simply Wall St on July 31, 2026. Earnings per share increased to EUR 2.41 from EUR 2.20.

What does the target mean for valuation?

Goldman Sachs added IMCD to its October European conviction list and set a 12-month target of EUR 133.00, according to Investire.biz on October 4, 2026. The bank's case centers on IMCD's specialized chemical and ingredient distribution, where formulation and technical support can add value beyond simple commodity trading.

Three dates frame the story

On July 31, 2026, first-half results showed EUR 2.65 billion of revenue and EUR 142.30 million of net income, as reported by Simply Wall St. On October 4, 2026, Goldman Sachs set its EUR 133.00 target through the report carried by Investire.biz. On October 15, 2026, IMCD announced the November 5 reporting date through Globenewswire.

Dates investors can mark

The next two scheduled dates are November 5, 2026, for the first nine-month results, and February 19, 2027, for full-year 2026 results, according to IMCD's investor-relations calendar.

Stock valuation stays central

IMCD's primary listing is on Euronext Amsterdam, where the company is included in the Dutch ESG AEX index. Its 2025 revenue was EUR 4.78 billion, up 5.00 percent on a constant-currency basis, while operating EBITA was EUR 497.80 million, down 3.00 percent on the same basis, according to the company's investor-relations information. That contrast leaves the November release with a clear task: show whether operating profit is improving faster than the recent revenue base.

IMCD stock closed at EUR 100.60 on Xetra on October 22, 2026. The 52-week range was EUR 68.14 to EUR 105.55 as of October 18, 2026, while market capitalization stood at EUR 5.8 billion on October 22, 2026.

The further course of trading is shown by the continuously updated real-time quote of IMCD stock.